Resumption of Intravenous Anti-Cancer Therapy in Breast Cancer: A Real-World Experience During the SARS-CoV-2 Pandemic

Overview

Journal Cancer Manag Res

Publisher Dove Medical Press

Specialty Oncology

Date 2024 Jan 9

PMID 38192402

Authors

Fang Yang

Cong Li

Yuling Qiu

Xinjie Chen

Kelin Zheng

Donglin Kang

Yin Zhang

Baorui Liu

Yongzhong Yao

Li Xie

Affiliations

Soon will be listed here.

Abstract

Purpose: The coronavirus disease-2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, has delayed medical consultations, especially for patients receiving intravenous anti-cancer therapy. We aim to investigate alterations in immune function among breast cancer patients who experience delayed intravenous therapy due to SARS-CoV-2 infection.

Patients And Methods: We performed an observational investigation of breast cancer patients in Nanjing Drum Tower Hospital from December 27, 2022, to January 20, 2023. Patients who recovered from SARS-CoV-2 infection were eligible for enrollment. Peripheral blood samples were taken prior to the restart of intravenous anti-cancer therapy to examine hematologic parameters.

Results: A total of 131 patients were included in the final analysis. Cough (74.0%), fever (62.6%), and expectoration (46.6%) were identified as the most presenting symptoms of SARS-CoV-2 infection in breast cancer. The average nucleic acid conversion time and delayed treatment time was 13.4 days and 13.9 days, respectively. The patients >60 years old experienced prolonged nucleic acid conversion time (P = 0.017) and delayed treatment time (P = 0.028) compared to those <= 60 years old. Dysregulated lymphocyte subsets and cytokines were found post-SARS-CoV-2 infection. Treatment-related adverse events of grade 3 or 4 occurred in 7.6% after resuming intravenous anti-cancer therapy.

Conclusion: Our findings reveal that the SARS-CoV-2 infection led to imbalanced immune responses and postponed intravenous anti-cancer therapy in breast cancer. The safety report encourages timely resumption of intravenous anti-cancer therapy after adequately weighing the risks and benefits.

References

Di Cosimo S, Ljevar S, Trama A, Bernasconi A, Lasalvia P, De Santis M . Direct and indirect effects of COVID-19 on short-term mortality of breast cancer patients. Breast. 2023; 71:60-62. PMC: 10413129. DOI: 10.1016/j.breast.2023.07.011. View

Lee L, Cazier J, Angelis V, Arnold R, Bisht V, Campton N . COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study. Lancet. 2020; 395(10241):1919-1926. PMC: 7255715. DOI: 10.1016/S0140-6736(20)31173-9. View

Alagoz O, Lowry K, Kurian A, Mandelblatt J, Ergun M, Huang H . Impact of the COVID-19 Pandemic on Breast Cancer Mortality in the US: Estimates From Collaborative Simulation Modeling. J Natl Cancer Inst. 2021; 113(11):1484-1494. PMC: 8344930. DOI: 10.1093/jnci/djab097. View

Richardson S, Hirsch J, Narasimhan M, Crawford J, McGinn T, Davidson K . Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. JAMA. 2020; 323(20):2052-2059. PMC: 7177629. DOI: 10.1001/jama.2020.6775. View

Mahmood S, Majid H, Arshad A, Zaib-Un-Nisa , Niazali N, Kazi K . Interleukin-6 (IL-6) as a Predictor of Clinical Outcomes in Patients with COVID-19. Clin Lab. 2023; 69(6). DOI: 10.7754/Clin.Lab.2022.220741. View

Tian J, Yuan X, Xiao J, Zhong Q, Yang C, Liu B . Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study. Lancet Oncol. 2020; 21(7):893-903. PMC: 7259911. DOI: 10.1016/S1470-2045(20)30309-0. View

Papautsky E, Hamlish T . Patient-reported treatment delays in breast cancer care during the COVID-19 pandemic. Breast Cancer Res Treat. 2020; 184(1):249-254. PMC: 7415197. DOI: 10.1007/s10549-020-05828-7. View

Prodhan A, Islam D, Khandker S, Jamiruddin M, Abdullah A, Godman B . Breast Cancer Management in the Era of Covid-19; Key Issues, Contemporary Strategies, and Future Implications. Breast Cancer (Dove Med Press). 2023; 15:51-89. PMC: 9888303. DOI: 10.2147/BCTT.S390296. View

Vanni G, Tazzioli G, Pellicciaro M, Materazzo M, Paolo O, Cattadori F . Delay in Breast Cancer Treatments During the First COVID-19 Lockdown. A Multicentric Analysis of 432 Patients. Anticancer Res. 2020; 40(12):7119-7125. DOI: 10.21873/anticanres.14741. View

10.

Zhang A, Morjaria S, Kaltsas A, Hohl T, Parameswaran R, Patel D . The Effect of Neutropenia and Filgrastim (G-CSF) on Cancer Patients With Coronavirus Disease 2019 (COVID-19) Infection. Clin Infect Dis. 2021; 74(4):567-574. PMC: 8406899. DOI: 10.1093/cid/ciab534. View

11.

Blanco-Melo D, Nilsson-Payant B, Liu W, Uhl S, Hoagland D, Moller R . Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19. Cell. 2020; 181(5):1036-1045.e9. PMC: 7227586. DOI: 10.1016/j.cell.2020.04.026. View

12.

Infante M, Salmanton-Garcia J, Fernandez-Cruz A, Marchesi F, Jaksic O, Weinbergerova B . B-cell malignancies treated with targeted drugs and SARS-CoV-2 infection: A European Hematology Association Survey (EPICOVIDEHA). Front Oncol. 2022; 12:992137. PMC: 9583921. DOI: 10.3389/fonc.2022.992137. View

13.

Zhang P, Du W, Yang T, Zhao L, Xiong R, Li Y . Lymphocyte subsets as a predictor of severity and prognosis in COVID-19 patients. Int J Immunopathol Pharmacol. 2021; 35:20587384211048567. PMC: 8504275. DOI: 10.1177/20587384211048567. View

14.

Eijkelboom A, de Munck L, Menke-van der Houven van Oordt C, Broeders M, van den Bongard D, Strobbe L . Changes in breast cancer treatment during the COVID-19 pandemic: a Dutch population-based study. Breast Cancer Res Treat. 2022; 197(1):161-175. PMC: 9638417. DOI: 10.1007/s10549-022-06732-y. View

15.

Hashemzadeh N, Dolatkhah M, Adibkia K, Aghanejad A, Barzegar-Jalali M, Omidi Y . Recent advances in breast cancer immunotherapy: The promising impact of nanomedicines. Life Sci. 2021; 271:119110. DOI: 10.1016/j.lfs.2021.119110. View

16.

Li J, Wang H, Geng C, Liu Z, Lin Y, Nie J . Suboptimal declines and delays in early breast cancer treatment after COVID-19 quarantine restrictions in China: A national survey of 8397 patients in the first quarter of 2020. EClinicalMedicine. 2020; 26:100503. PMC: 7511845. DOI: 10.1016/j.eclinm.2020.100503. View

17.

Tope P, Farah E, Ali R, El-Zein M, Miller W, Franco E . The impact of lag time to cancer diagnosis and treatment on clinical outcomes prior to the COVID-19 pandemic: A scoping review of systematic reviews and meta-analyses. Elife. 2023; 12. PMC: 9928418. DOI: 10.7554/eLife.81354. View

18.

Kutikov A, Weinberg D, Edelman M, Horwitz E, Uzzo R, Fisher R . A War on Two Fronts: Cancer Care in the Time of COVID-19. Ann Intern Med. 2020; 172(11):756-758. PMC: 7133056. DOI: 10.7326/M20-1133. View

19.

Lee K, Ma W, Sikavi D, Drew D, Nguyen L, Bowyer R . Cancer and Risk of COVID-19 Through a General Community Survey. Oncologist. 2020; 26(1). PMC: 7460944. DOI: 10.1634/theoncologist.2020-0572. View

20.

Zhao Y, Shang Y, Song W, Li Q, Xie H, Xu Q . Follow-up study of the pulmonary function and related physiological characteristics of COVID-19 survivors three months after recovery. EClinicalMedicine. 2020; 25:100463. PMC: 7361108. DOI: 10.1016/j.eclinm.2020.100463. View